VIDEO: Faricimab shows good visual stability, extended treatment intervals at 1 year
Click Here to Manage Email Alerts
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Ferhina S. Ali, MD, MPH, presents real-world data from the FARETINA-AMD study investigating faricimab for the treatment of neovascular age-related macular degeneration.
“What we saw with our patients that were getting faricimab over our study period, which was soon after drug approval, is that most of these patients were not treatment naïve and that they had been on treatment prior. Most of them had been on treatment with aflibercept and they were switched to faricimab treatment,” she said. “We saw good vision stability with the use of faricimab and we also saw that the treatment intervals were rapidly extended early on in the treatment course for these patients.”
Collapse
Ali FS. Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with faricimab: The FARETINA-AMD study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts